10-Q: Acro Biomedical Reports Q2 2025 Loss, Zero Revenue

Acro Biomedical Co., Ltd. reported continued net losses and no revenue for the second quarter and first half of 2025, raising substantial doubt about its ability to continue as a going concern.

Summary

• Reported a net loss of $15,562 for the three months ended June 30, 2025, compared to $10,143 for the same period in 2024.
• Incurred a net loss of $25,863 for the six months ended June 30, 2025, up from $21,395 in the prior year period.
• Generated no revenue for the three and six months ended June 30, 2025, and has not had any sales since December 31, 2022.
• Cash balance stood at a minimal $26 as of June 30, 2025, down from $476 at December 31, 2024.
• Total liabilities increased to $370,797 as of June 30, 2025, from $326,946 at December 31, 2024.
• Working capital deficiency worsened to $331,171 as of June 30, 2025, from $321,870 at December 31, 2024.
• Relied heavily on advances from a minority stockholder, totaling $116,065 for the six months ended June 30, 2025, to cover operating cash outflows.

Sentiment

Score: 1

Explanation: The company faces severe financial distress, including no revenue, increasing losses, minimal cash, significant going concern doubt, and ineffective internal controls. Its stock is illiquid, and future funding is uncertain, indicating an extremely negative outlook.

Positives

• Continued financial support from a minority stockholder, providing $116,065 in advances for the six months ended June 30, 2025, which is currently the primary source of funds.
• Total assets increased to $53,277 as of June 30, 2025, from $31,974 at December 31, 2024, primarily due to an increase in prepaid expenses.

Negatives

• No revenue generated for the three and six months ended June 30, 2025, extending the period without sales since December 31, 2022.
• Increased net loss for the six months ended June 30, 2025, to $25,863 from $21,395 in the prior year.
• Minimal cash balance of $26 as of June 30, 2025, indicating severe liquidity issues.
• Substantial doubt about the ability to continue as a going concern due to lack of revenue, recurring losses, and negative cash flows from operations.
• Significant reliance on related party advances for funding, with no assurance of continued support.
• Common stock trades on the OTC Pink Limited Market, lacking market makers and eligible only for unsolicited customer orders, leading to high risk of volatility and illiquidity.
• Disclosure controls were deemed ineffective as of June 30, 2025, due to inadequate internal controls, lack of segregation of duties, and reliance on a single part-time CEO/CFO.
• Past research and development activities (cordyceps-infused chicken feed) did not generate a marketable product.
• The company has no full-time employees, and its CEO/CFO works part-time without compensation, which does not reflect normal operational costs.

Risks

• Going Concern: Substantial doubt exists about the ability to continue as a going concern due to minimal cash, no revenue since December 31, 2022, recurring losses, and negative operating cash flows.
• Funding Dependence: Heavy reliance on advances from a minority stockholder, with no guarantee of continued funding, poses a significant risk to future operations.
• Capital Raising Challenges: Difficulty in raising funds through equity financing due to the company's financial condition, lack of sales, and the illiquid trading market for its common stock (OTC Pink Limited, no market makers).
• Market Illiquidity: The common stock trades on the OTC Pink Limited Market, is not eligible for proprietary broker-dealer quotes, and has no market makers, making it difficult for investors to sell and increasing volatility and price dislocations.
• Operational Inability: Inability to develop or market products, increase customer base, improve supply chain, or achieve significant gross margins, which could prevent revenue generation.
• Personnel & R&D: Challenges in hiring and retaining qualified research and development, marketing, and administrative personnel, especially given the inability to offer competitive compensation or attractive equity due to stock illiquidity.
• Regulatory Compliance: Risks associated with complying with government regulations for the manufacture, distribution, and marketing of any potential products.
• Macroeconomic Factors: Potential material impairment from inflationary pressures, supply chain disruptions, and increased tariffs, although the company has not made sales or purchased inventory since December 31, 2022.
• Geopolitical Risks: Political instability in Hong Kong and the aftereffects of China's COVID-19 restrictions could continue to affect sales and customer payments, as past customers were Hong Kong-based and sold into the PRC.
• Internal Control Weaknesses: Material weaknesses in internal controls over financial reporting, including absence of segregation of duties, lack of qualified accounting personnel, and excessive reliance on third-party consultants, leading to ineffective disclosure controls.

Future Outlook

The company proposes to fund operations through product sales and equity financing arrangements, but currently has no product orders or agreements for funding. Management cannot assure the development of marketable products or the generation of future revenue or profits. There is no assurance that a broker-dealer will make a market in its common stock, which is crucial for equity financing.

Management Comments

• "We cannot assure you that we can or will develop any products or generate revenue or profits in the future."
• "We do not have the funds or the revenue stream for us to hire any consultants or employees."
• "Our primary source of funds for the years ended December 31, 2024 and 2023 and the six months ended June 30, 2025 has been advances from a minority stockholder. This stockholder has continued to be our principal source of funds. We cannot assure you that he will continue to provide funding for us."
• "Because we are quoted on the Pink Limited Market, our common stock is an unsolicited only stock and there are no market makers for our common stock, potential employees or consultants may be reluctant to accept common stock as compensation."
• "Our disclosure controls were not effective as of June 30, 2025, due to the inadequacy of our internal controls over financial reporting, our sole employee being our chief executive and financial officer and our limited internal audit function."

Industry Context

The company operates in the traditional Chinese medicine and nutritional products sector, specifically focusing on cordyceps-related products. Its historical sales were significantly impacted by China's Zero COVID policy and political instability in Hong Kong, highlighting the vulnerability to geopolitical and public health policies in key markets. The broader industry faces inflationary pressures and supply chain disruptions, which could further impede the company's ability to resume operations and generate revenue.

Comparison to Industry Standards

• The company's complete lack of revenue since December 31, 2022, and consistent net losses place it significantly below industry standards for operational health and financial performance.
• Unlike established biomedical or nutritional product companies that demonstrate consistent revenue streams, product development pipelines, and market presence, Acro Biomedical has failed to generate a marketable product from its R&D efforts and has no current product orders.
• The reliance on related party advances for basic operational funding, rather than commercial sales or institutional financing, is a stark contrast to typical industry funding models.
• The illiquid trading status of its common stock on the OTC Pink Limited Market, without market makers, is far from the robust trading environments of publicly listed peers in the health and wellness sector.

Corporate Governance

Related Party Transactions

• A minority stockholder advanced $0 and paid expenses of $116,065 on behalf of the company during the six months ended June 30, 2025.
• The company owed $240,553 to the minority stockholder as of June 30, 2025, for non-interest-bearing advances and paid expenses, due on demand.
• The company owed $1,100 to its chief executive officer as of June 30, 2025, for non-interest-bearing advances and paid expenses, due on demand.
• Imputed interest at 4% on related party advances amounted to $3,315 for the six months ended June 30, 2025.
• A minority stockholder paid the security deposit ($4,600) and monthly rent (HK$17,900/month) for a storage facility in Hong Kong.

Stakeholder Impact

• Shareholders: Face significant risk of investment loss due to going concern doubt, lack of revenue, recurring losses, and an illiquid trading market for common stock. Potential for significant dilution if equity financing is secured.
• Creditors (Related Parties): Bear the primary financial risk by providing ongoing advances to fund operations without assurance of repayment.
• Employees (CEO): Works part-time without compensation, indicating a lack of sustainable compensation structure and potential for burnout or departure.
• Customers: No current customers or product orders, indicating no immediate impact.

Next Steps

• Seek to fund operations through sales of products and equity financing arrangements.
• Potentially seek to market other products complementary to its current offerings.
• Address the material weaknesses in internal controls over financial reporting.

Key Dates

Recommendation

The company exhibits severe financial distress with no revenue since December 2022, increasing net losses, and a critically low cash balance of $26. The explicit 'going concern' doubt, coupled with heavy reliance on uncertain related-party funding and ineffective internal controls, points to an unsustainable business model. The common stock's illiquid trading status on the OTC Pink Limited Market further exacerbates investment risk. There are no discernible positive catalysts, and the fundamental issues suggest a high probability of further value erosion or business failure.

Keywords

Acro Biomedical, Cordyceps, Traditional Chinese Medicine, OTC Pink Limited, Going Concern, Biomedical Products, Nutritional Supplements, Financial Reporting, SEC 10-Q, Related Party Transactions, Liquidity Risk, Corporate Governance